CAR-T Referral Process: Insights from UCSF : Episode 6
Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers
Panelists discuss how, a collaborative approach to co-managing and co-monitoring patients receiving CAR-TCAR T-cell therapy patients, ensuring continuity of care as they transition to community settings. We They employ detailed care plans, electronic health records integration, and regular follow-ups with community providers to facilitate seamless transitions.
EP: 1.Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma
EP: 2.Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment
EP: 3.Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?
EP: 4.Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection
EP: 5.CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy
Now Viewing
EP: 6.Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers
EP: 7.Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies
Video content above is prompted by the following:
- Describe your institution’'s approach to the co-management and co-monitoring of patients receiving CAR-TCAR T-cell therapy, particularly in the transition back to the community setting.
- Can you share any specific strategies or tools your institution utilizes to facilitate seamless transitions of care between the academic center and community practices for patients receiving CAR-TCAR T-cell therapy patients?
Recent Videos
Related Content
